お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、ヒト凝固第VIII因子の世界市場、容量、生産量、収益、価格の概要を紹介します。2020~2024年の歴史的な市場収益/売上データ、2025年の予想、および2031年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にヒト凝固第VIII因子市場を分類しています。
本レポートでは世界のヒト凝固第VIII因子市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Takeda、Bayer、CSL、Pfizer、Grifols、Biogen、Octapharma、NovoNordisk、Greencross、Kedrion、BPL、Hualan Bio、RAAS、SinoCellTech、Taibang Bio、Huarun Boya、Shuanglin Bio、Yuandashuyang、Weiguang Bio

レポートはヒト凝固第VIII因子の主要生産者を調査し、主要地域や国の消費状況も提供します。ヒト凝固第VIII因子の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2020年から2031年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Recombinant Factor VIII
    Plasma-derived Factor VIII

用途別の市場セグメント：
    Hemophilia A
    Spontanous / Trauma
    Surgical
    Other

本レポートの詳細内容
本レポートは、世界のヒト凝固第VIII因子市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてヒト凝固第VIII因子市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2020年から2025年まで、そして2031年までの予測として、メーカー別、地域別（地域レベル、国レベル）のヒト凝固第VIII因子生産量、成長率、市場シェアを調査している。

二. 消費面では、ヒト凝固第VIII因子の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2020年から2025年まで、2031年までの予測。

三.主要メーカーのヒト凝固第VIII因子売上高、収益、市場シェア、業界ランキング、2020年から2025年までのデータに焦点を当てています。世界のヒト凝固第VIII因子市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本ヒト凝固第VIII因子のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：ヒト凝固第VIII因子のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2020～2031）
第2章： ヒト凝固第VIII因子の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2020～2031）
第3章：世界、地域、国レベルにおけるヒト凝固第VIII因子の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2020～2031）
第4章ヒト凝固第VIII因子メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2020～2025）
第5章：ヒト凝固第VIII因子の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2020～2031）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2020～2031）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2020～2031）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2020～2031）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2020～2031）
第12章：ヒト凝固第VIII因子の主要メーカーの概要を提供し、製品の説明と仕様、ヒト凝固第VIII因子の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2020～2025）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：ヒト凝固第VIII因子の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

Valued at US$ 12200 million in 2024, the global Human Coagulation Factor VIII market is forecast to reach US$ 17610 million by 2030, at a CAGR of 6.3% during the forecast period.
Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A. Human Coagulation Factor VIII concentrated from donated blood plasma (Aafact or Alphanate, Monoclate-P®), or alternatively recombinant Human Coagulation Factor VIII can be given to hemophiliacs to restore hemostasis.
Market Drivers:
The increasing prevalence of hemophilia A is a key driver for the Human Coagulation Factor VIII market. As awareness and diagnosis rates improve, more patients are receiving proper treatment, driving demand for Factor VIII therapies. Additionally, advancements in biotechnology, including the development of recombinant and extended half-life Factor VIII products, have significantly improved treatment efficacy and patient convenience. Government initiatives and healthcare programs supporting rare disease treatments, along with expanded access to hemophilia care in developing regions, further boost market growth. The rise of gene therapy research also presents potential future opportunities for transforming the hemophilia treatment landscape.
Market Challenges:
Despite strong market growth, several challenges persist, including the high cost of Factor VIII therapies, which limits affordability and accessibility for many patients, especially in low-income regions. Additionally, plasma-derived Factor VIII products face supply chain constraints due to reliance on blood donations. Another major challenge is the development of inhibitors (antibodies) in some patients, which can render Factor VIII treatment ineffective and necessitate alternative therapies. Regulatory complexities and the need for stringent quality control in manufacturing also pose barriers for new entrants in the market.
Report Includes
This report presents an overview of global market for Human Coagulation Factor VIII, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Human Coagulation Factor VIII, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Human Coagulation Factor VIII, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Human Coagulation Factor VIII sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Human Coagulation Factor VIII market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Human Coagulation Factor VIII sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Takeda, Bayer, CSL, Pfizer, Grifols, Biogen, Octapharma, NovoNordisk, Greencross, Kedrion, etc.

Market Segmentation
By Company
    Takeda
    Bayer
    CSL
    Pfizer
    Grifols
    Biogen
    Octapharma
    NovoNordisk
    Greencross
    Kedrion
    BPL
    Hualan Bio
    RAAS
    SinoCellTech
    Taibang Bio
    Huarun Boya
    Shuanglin Bio
    Yuandashuyang
    Weiguang Bio

Segment by Type
    Recombinant Factor VIII
    Plasma-derived Factor VIII

Segment by Application
    Hemophilia A
    Spontanous / Trauma
    Surgical
    Other

Segment by region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
        Southeast Asia
        India
        Australia
    Europe
        Germany
        France
        U.K.
        Italy
        Russia

Middle East, Africa, Latin America
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Human Coagulation Factor VIII in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Human Coagulation Factor VIII manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Human Coagulation Factor VIII sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
 Table 1. Global Human Coagulation Factor VIII Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Table 2. Major Manufacturers of Recombinant Factor VIII
 Table 3. Major Manufacturers of Plasma-derived Factor VIII
 Table 4. Global Human Coagulation Factor VIII Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Table 5. Global Human Coagulation Factor VIII Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 6. Global Revenue by Region (2020-2025) & (US$ Million)
 Table 7. Global Revenue Market Share by Region (2020-2031)
 Table 8. Global Human Coagulation Factor VIII Sales Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (K Bottles)
 Table 9. Global Human Coagulation Factor VIII Sales by Region (2020-2031) & (K Bottles)
 Table 10. Global Sales Market Share by Region (2020-2031)
 Table 11. Global Human Coagulation Factor VIII Sales by Manufacturers (2020-2025) & (K Bottles)
 Table 12. Global Human Coagulation Factor VIII Sales Share by Manufacturers (2020-2025)
 Table 13. Global Human Coagulation Factor VIII Revenue by Manufacturers (2020-2025) & (US$ Million)
 Table 14. Global Human Coagulation Factor VIII Revenue Market Share by Manufacturers (2020-2025)
 Table 15. Global Key Players of Human Coagulation Factor VIII, Industry Ranking, 2023 VS 2024 VS 2024
 Table 16. Human Coagulation Factor VIII Price by Manufacturers (2020-2025) & (USD/Bottle)
 Table 17. Global Human Coagulation Factor VIII Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 18. Global Human Coagulation Factor VIII by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Human Coagulation Factor VIII as of 2024)
 Table 19. Global Key Manufacturers of Human Coagulation Factor VIII, Manufacturing Base Distribution and Headquarters
 Table 20. Global Key Manufacturers of Human Coagulation Factor VIII, Product Offered and Application
 Table 21. Global Key Manufacturers of Human Coagulation Factor VIII, Date of Enter into This Industry
 Table 22. Mergers & Acquisitions, Expansion Plans
 Table 23. Global Human Coagulation Factor VIII Sales by Type (2020-2025) & (K Bottles)
 Table 24. Global Human Coagulation Factor VIII Sales by Type (2026-2031) & (K Bottles)
 Table 25. Global Sales Share by Type (2020-2031)
 Table 26. Global Human Coagulation Factor VIII Revenue by Type (2020-2025) & (US$ Million)
 Table 27. Global Human Coagulation Factor VIII Revenue by Type (2026-2031) & (US$ Million)
 Table 28. Global Revenue Share by Type (2020-2031)
 Table 29. Human Coagulation Factor VIII Price by Type (2020-2025) & (USD/Bottle)
 Table 30. Global Human Coagulation Factor VIII Price Forecast by Type (2026-2031) & (USD/Bottle)
 Table 31. Global Human Coagulation Factor VIII Sales by Application (2020-2025) & (K Bottles)
 Table 32. Global Human Coagulation Factor VIII Sales by Application (2026-2031) & (K Bottles)
 Table 33. Global Sales Share by Application (2020-2031)
 Table 34. Global Human Coagulation Factor VIII Revenue by Application (2020-2025) & (US$ Million)
 Table 35. Global Human Coagulation Factor VIII Revenue by Application (2026-2031) & (US$ Million)
 Table 36. Global Revenue Share by Application (2020-2031)
 Table 37. Human Coagulation Factor VIII Price by Application (2020-2025) & (USD/Bottle)
 Table 38. Global Human Coagulation Factor VIII Price Forecast by Application (2026-2031) & (USD/Bottle)
 Table 39. US & Canada Sales by Type (2020-2031) & (K Bottles)
 Table 40. US & Canada Revenue by Type (2020-2031) & (US$ Million)
 Table 41. US & Canada Sales by Application (2020-2031) & (K Bottles)
 Table 42. US & Canada Revenue by Application (2020-2031) & (US$ Million)
 Table 43. US & Canada Human Coagulation Factor VIII Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 44. US & Canada Revenue by Country (2020-2031) & (US$ Million)
 Table 45. US & Canada Sales by Country (2020-2031) & (K Bottles)
 Table 46. Europe Sales by Type (2020-2031) & (K Bottles)
 Table 47. Europe Revenue by Type (2020-2031) & (US$ Million)
 Table 48. Europe Sales by Application (2020-2031) & (K Bottles)
 Table 49. Europe Revenue by Application (2020-2031) & (US$ Million)
 Table 50. Europe Human Coagulation Factor VIII Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 51. Europe Sales by Country (2020-2031) & (K Bottles)
 Table 52. Europe Revenue by Country (2020-2031) & (US$ Million)
 Table 53. China Sales by Type (2020-2031) & (K Bottles)
 Table 54. China Revenue by Type (2020-2031) & (US$ Million)
 Table 55. China Sales by Application (2020-2031) & (K Bottles)
 Table 56. China Revenue by Application (2020-2031) & (US$ Million)
 Table 57. Asia Sales by Type (2020-2031) & (K Bottles)
 Table 58. Asia Revenue by Type (2020-2031) & (US$ Million)
 Table 59. Asia Sales by Application (2020-2031) & (K Bottles)
 Table 60. Asia Revenue by Application (2020-2031) & (US$ Million)
 Table 61. Asia Human Coagulation Factor VIII Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 62. Asia Revenue by Region (2020-2031) & (US$ Million)
 Table 63. Asia Sales by Region (2020-2031) & (K Bottles)
 Table 64. Middle East, Africa and Latin America Sales by Type (2020-2031) & (K Bottles)
 Table 65. Middle East, Africa and Latin America Revenue by Type (2020-2031) & (US$ Million)
 Table 66. Middle East, Africa and Latin America Sales by Application (2020-2031) & (K Bottles)
 Table 67. Middle East, Africa and Latin America Revenue by Application (2020-2031) & (US$ Million)
 Table 68. Middle East, Africa and Latin America Human Coagulation Factor VIII Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 69. Middle East, Africa and Latin America Revenue by Country (2020-2031) & (US$ Million)
 Table 70. Middle East, Africa and Latin America Sales by Country (2020-2031) & (K Bottles)
 Table 71. Takeda Company Information
 Table 72. Takeda Description and Major Businesses
 Table 73. Takeda Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 74. Takeda Product Model Numbers, Pictures, Descriptions and Specifications
 Table 75. Takeda Recent Developments
 Table 76. Bayer Company Information
 Table 77. Bayer Description and Major Businesses
 Table 78. Bayer Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 79. Bayer Product Model Numbers, Pictures, Descriptions and Specifications
 Table 80. Bayer Recent Developments
 Table 81. CSL Company Information
 Table 82. CSL Description and Major Businesses
 Table 83. CSL Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 84. CSL Product Model Numbers, Pictures, Descriptions and Specifications
 Table 85. CSL Recent Developments
 Table 86. Pfizer Company Information
 Table 87. Pfizer Description and Major Businesses
 Table 88. Pfizer Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 89. Pfizer Product Model Numbers, Pictures, Descriptions and Specifications
 Table 90. Pfizer Recent Developments
 Table 91. Grifols Company Information
 Table 92. Grifols Description and Major Businesses
 Table 93. Grifols Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 94. Grifols Product Model Numbers, Pictures, Descriptions and Specifications
 Table 95. Grifols Recent Developments
 Table 96. Biogen Company Information
 Table 97. Biogen Description and Major Businesses
 Table 98. Biogen Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 99. Biogen Product Model Numbers, Pictures, Descriptions and Specifications
 Table 100. Biogen Recent Developments
 Table 101. Octapharma Company Information
 Table 102. Octapharma Description and Major Businesses
 Table 103. Octapharma Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 104. Octapharma Product Model Numbers, Pictures, Descriptions and Specifications
 Table 105. Octapharma Recent Developments
 Table 106. NovoNordisk Company Information
 Table 107. NovoNordisk Description and Major Businesses
 Table 108. NovoNordisk Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 109. NovoNordisk Product Model Numbers, Pictures, Descriptions and Specifications
 Table 110. NovoNordisk Recent Developments
 Table 111. Greencross Company Information
 Table 112. Greencross Description and Major Businesses
 Table 113. Greencross Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 114. Greencross Product Model Numbers, Pictures, Descriptions and Specifications
 Table 115. Greencross Recent Developments
 Table 116. Kedrion Company Information
 Table 117. Kedrion Description and Major Businesses
 Table 118. Kedrion Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 119. Kedrion Product Model Numbers, Pictures, Descriptions and Specifications
 Table 120. Kedrion Recent Developments
 Table 121. BPL Company Information
 Table 122. BPL Description and Major Businesses
 Table 123. BPL Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 124. BPL Product Model Numbers, Pictures, Descriptions and Specifications
 Table 125. BPL Recent Developments
 Table 126. Hualan Bio Company Information
 Table 127. Hualan Bio Description and Major Businesses
 Table 128. Hualan Bio Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 129. Hualan Bio Product Model Numbers, Pictures, Descriptions and Specifications
 Table 130. Hualan Bio Recent Developments
 Table 131. RAAS Company Information
 Table 132. RAAS Description and Major Businesses
 Table 133. RAAS Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 134. RAAS Product Model Numbers, Pictures, Descriptions and Specifications
 Table 135. RAAS Recent Developments
 Table 136. SinoCellTech Company Information
 Table 137. SinoCellTech Description and Major Businesses
 Table 138. SinoCellTech Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 139. SinoCellTech Product Model Numbers, Pictures, Descriptions and Specifications
 Table 140. SinoCellTech Recent Developments
 Table 141. Taibang Bio Company Information
 Table 142. Taibang Bio Description and Major Businesses
 Table 143. Taibang Bio Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 144. Taibang Bio Product Model Numbers, Pictures, Descriptions and Specifications
 Table 145. Taibang Bio Recent Developments
 Table 146. Huarun Boya Company Information
 Table 147. Huarun Boya Description and Major Businesses
 Table 148. Huarun Boya Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 149. Huarun Boya Product Model Numbers, Pictures, Descriptions and Specifications
 Table 150. Huarun Boya Recent Developments
 Table 151. Shuanglin Bio Company Information
 Table 152. Shuanglin Bio Description and Major Businesses
 Table 153. Shuanglin Bio Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 154. Shuanglin Bio Product Model Numbers, Pictures, Descriptions and Specifications
 Table 155. Shuanglin Bio Recent Developments
 Table 156. Yuandashuyang Company Information
 Table 157. Yuandashuyang Description and Major Businesses
 Table 158. Yuandashuyang Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 159. Yuandashuyang Product Model Numbers, Pictures, Descriptions and Specifications
 Table 160. Yuandashuyang Recent Developments
 Table 161. Weiguang Bio Company Information
 Table 162. Weiguang Bio Description and Major Businesses
 Table 163. Weiguang Bio Sales (K Bottles), Revenue (US$ Million), Price (USD/Bottle) and Gross Margin (2020-2025)
 Table 164. Weiguang Bio Product Model Numbers, Pictures, Descriptions and Specifications
 Table 165. Weiguang Bio Recent Developments
 Table 166. Key Raw Materials Lists
 Table 167. Raw Materials Key Suppliers Lists
 Table 168. Distributors List
 Table 169. Customers List
 Table 170. Market Trends
 Table 171. Market Drivers
 Table 172. Market Challenges
 Table 173. Market Restraints
 Table 174. Research Programs/Design for This Report
 Table 175. Key Data Information from Secondary Sources
 Table 176. Key Data Information from Primary Sources


List of Figures
 Figure 1. Human Coagulation Factor VIII Product Picture
 Figure 2. Global Human Coagulation Factor VIII Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 3. Global Human Coagulation Factor VIII Market Share by Type: 2024 & 2031
 Figure 4. Recombinant Factor VIII Product Picture
 Figure 5. Plasma-derived Factor VIII Product Picture
 Figure 6. Global Human Coagulation Factor VIII Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
 Figure 7. Global Human Coagulation Factor VIII Market Share by Application: 2024 & 2031
 Figure 8. Hemophilia A
 Figure 9. Spontanous / Trauma
 Figure 10. Surgical
 Figure 11. Other
 Figure 12. Human Coagulation Factor VIII Report Years Considered
 Figure 13. Global Human Coagulation Factor VIII Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 14. Global Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 15. Global Human Coagulation Factor VIII Revenue by Region (2020-2031) (US$ Million)
 Figure 16. Global Human Coagulation Factor VIII Revenue Market Share by Region in Percentage: 2024 Versus 2031
 Figure 17. Global Human Coagulation Factor VIII Revenue Market Share by Region (2020-2031)
 Figure 18. Global Human Coagulation Factor VIII Sales (2020-2031) & (K Bottles)
 Figure 19. Global Human Coagulation Factor VIII Sales (CAGR) by Region: 2020 VS 2024 VS 2031 (K Bottles)
 Figure 20. Global Human Coagulation Factor VIII Sales Market Share by Region (2020-2031)
 Figure 21. US & Canada Human Coagulation Factor VIII Sales YoY (2020-2031) & (K Bottles)
 Figure 22. US & Canada Human Coagulation Factor VIII Revenue YoY (2020-2031) & (US$ Million)
 Figure 23. Europe Human Coagulation Factor VIII Sales YoY (2020-2031) & (K Bottles)
 Figure 24. Europe Human Coagulation Factor VIII Revenue YoY (2020-2031) & (US$ Million)
 Figure 25. China Human Coagulation Factor VIII Sales YoY (2020-2031) & (K Bottles)
 Figure 26. China Human Coagulation Factor VIII Revenue YoY (2020-2031) & (US$ Million)
 Figure 27. Asia (excluding China) Human Coagulation Factor VIII Sales YoY (2020-2031) & (K Bottles)
 Figure 28. Asia (excluding China) Human Coagulation Factor VIII Revenue YoY (2020-2031) & (US$ Million)
 Figure 29. Middle East, Africa and Latin America Human Coagulation Factor VIII Sales YoY (2020-2031) & (K Bottles)
 Figure 30. Middle East, Africa and Latin America Human Coagulation Factor VIII Revenue YoY (2020-2031) & (US$ Million)
 Figure 31. Global Human Coagulation Factor VIII Sales Share by Manufacturers (2024)
 Figure 32. The Human Coagulation Factor VIII Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2024
 Figure 33. Global Human Coagulation Factor VIII Revenue Share by Manufacturers (2024)
 Figure 34. The Top 5 and 10 Largest Manufacturers of Human Coagulation Factor VIII in the World: Market Share by Human Coagulation Factor VIII Revenue in 2024
 Figure 35. Global Human Coagulation Factor VIII Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 36. Global Human Coagulation Factor VIII Sales Market Share by Type (2020-2031)
 Figure 37. Global Human Coagulation Factor VIII Revenue Market Share by Type (2020-2031)
 Figure 38. Global Human Coagulation Factor VIII Sales Market Share by Application (2020-2031)
 Figure 39. Global Human Coagulation Factor VIII Revenue Market Share by Application (2020-2031)
 Figure 40. US & Canada Human Coagulation Factor VIII Sales Market Share by Type (2020-2031)
 Figure 41. US & Canada Human Coagulation Factor VIII Revenue Market Share by Type (2020-2031)
 Figure 42. US & Canada Human Coagulation Factor VIII Sales Market Share by Application (2020-2031)
 Figure 43. US & Canada Human Coagulation Factor VIII Revenue Market Share by Application (2020-2031)
 Figure 44. US & Canada Human Coagulation Factor VIII Revenue Share by Country (2020-2031)
 Figure 45. US & Canada Human Coagulation Factor VIII Sales Share by Country (2020-2031)
 Figure 46. US Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 47. Canada Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 48. Europe Human Coagulation Factor VIII Sales Market Share by Type (2020-2031)
 Figure 49. Europe Human Coagulation Factor VIII Revenue Market Share by Type (2020-2031)
 Figure 50. Europe Human Coagulation Factor VIII Sales Market Share by Application (2020-2031)
 Figure 51. Europe Human Coagulation Factor VIII Revenue Market Share by Application (2020-2031)
 Figure 52. Europe Human Coagulation Factor VIII Sales Share by Country (2020-2031)
 Figure 53. Europe Human Coagulation Factor VIII Revenue Share by Country (2020-2031)
 Figure 54. Germany Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 55. France Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 56. U.K. Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 57. Italy Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 58. Russia Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 59. China Human Coagulation Factor VIII Sales Market Share by Type (2020-2031)
 Figure 60. China Human Coagulation Factor VIII Revenue Market Share by Type (2020-2031)
 Figure 61. China Human Coagulation Factor VIII Sales Market Share by Application (2020-2031)
 Figure 62. China Human Coagulation Factor VIII Revenue Market Share by Application (2020-2031)
 Figure 63. Asia Human Coagulation Factor VIII Sales Market Share by Type (2020-2031)
 Figure 64. Asia Human Coagulation Factor VIII Revenue Market Share by Type (2020-2031)
 Figure 65. Asia Human Coagulation Factor VIII Sales Market Share by Application (2020-2031)
 Figure 66. Asia Human Coagulation Factor VIII Revenue Market Share by Application (2020-2031)
 Figure 67. Asia Human Coagulation Factor VIII Revenue Share by Region (2020-2031)
 Figure 68. Asia Human Coagulation Factor VIII Sales Share by Region (2020-2031)
 Figure 69. Japan Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 70. South Korea Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 71. China Taiwan Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 72. Southeast Asia Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 73. India Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 74. Australia Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 75. Middle East, Africa and Latin America Human Coagulation Factor VIII Sales Market Share by Type (2020-2031)
 Figure 76. Middle East, Africa and Latin America Human Coagulation Factor VIII Revenue Market Share by Type (2020-2031)
 Figure 77. Middle East, Africa and Latin America Human Coagulation Factor VIII Sales Market Share by Application (2020-2031)
 Figure 78. Middle East, Africa and Latin America Human Coagulation Factor VIII Revenue Market Share by Application (2020-2031)
 Figure 79. Middle East, Africa and Latin America Human Coagulation Factor VIII Revenue Share by Country (2020-2031)
 Figure 80. Middle East, Africa and Latin America Human Coagulation Factor VIII Sales Share by Country (2020-2031)
 Figure 81. Brazil Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 82. Mexico Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 83. Turkey Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 84. Israel Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 85. GCC Countries Human Coagulation Factor VIII Revenue (2020-2031) & (US$ Million)
 Figure 86. Value Chain
 Figure 87. Human Coagulation Factor VIII Production Process
 Figure 88. Channels of Distribution (Direct Vs Distribution)
 Figure 89. Bottom-up and Top-down Approaches for This Report
 Figure 90. Data Triangulation
 Figure 91. Key Executives Interviewed